CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced that it has structured its management team for future growth by promoting and expanding the areas of responsibility for members of its management team. Andrew Hirsch has been appointed Chief Operating Officer with expanded responsibilities, including program and alliance management and oversight of BIND's Russian operations. Andrew will continue to serve as Chief Financial Officer of the company. Jeff Hrkach, Ph.D., formerly Senior Vice President, Technology Research and Development, has been promoted to Chief Technology Officer with responsibility for the research, development and manufacturing of BIND's Accurin pipeline and research and technology development related to BIND's Medicinal Nanoengineering® platform.
In addition to Andrew and Jeff, BIND's senior management team includes Dan Koerwer, who was promoted to Senior Vice President of Business Development and Commercial in 2013, and Scott Minick, BIND's Chief Executive Officer. James Wright, Ph.D., formerly Chief Scientific Officer, will continue with BIND in the role of Distinguished Research Fellow, reporting to Dr. Hrkach.
"With BIND-014 in Phase 2 clinical development and our pipeline and partnership programs continuing to advance, we have strengthened BIND's leadership by increasing and expanding the responsibilities of key management team members. I am pleased to recognize Andrew and Jeff's many accomplishments and their important roles at BIND going forward as we continue building a leading nanomedicine platform company," said Mr. Minick.
"Andrew has clearly demonstrated his skill in managing a range of critical functions which will be valuable in his new role as Chief Operating Officer," Mr. Minick continued. "Jeff has been an outstanding leader in developing BIND's technology platform to generate multiple product candidates and we look forward to his further contributions to expand our pipeline and advance BIND's R&D capabilities. Dan has led the formation of three major partnerships with Amgen, Pfizer and AstraZeneca and will continue to identify collaboration opportunities to expand BIND's technology platform and product opportunities in the future as well as lead strategy and commercial development at BIND."
Andrew Hirsch has served as BIND's Chief Financial Officer since July 2012. Prior to that, he was Vice President of Finance and Chief Financial Officer at Avila Therapeutics, Inc., a biotechnology company, until its acquisition by Celgene Corporation. From 2002 to 2011, Mr. Hirsch served in roles of increasing responsibility during his nearly ten-year tenure at Biogen Idec, a biotechnology company, including the most recent role from 2010 to 2011 as Vice President, Corporate Strategy and M&A. From 2007 to 2010, Mr. Hirsch held various positions in the finance organization at Biogen Idec including leading the company's Business Planning and Investor Relations functions. In addition, he served as Program Executive in neurology, leading the development teams at Biogen Idec for the BG-12 (now marketed as Tecfidera), Avonex and Tysabri programs. He received his M.B.A. from the Tuck School at Dartmouth College and a B.A. in Economics from the University of Pennsylvania.
Jeff Hrkach has served as BIND's Senior Vice President, Technology, Research and Development since January 2010. From August 2009 to January 2010, he served as BIND's Interim President. Prior to serving as Interim President, he served as Vice President of Pharmaceutical Sciences at BIND from July 2007 to August 2009. Prior to joining BIND, Dr. Hrkach was Senior Director of Drug Delivery and Strategic Product Development at Momenta Pharmaceuticals, Inc. Prior to Momenta, Dr. Hrkach was Director of Pulmonary Formulations at Alkermes. Dr. Hrkach joined Advanced Inhalation Research (AIR) at its inception in 1998 following his postdoctoral research with Professor Robert Langer at the Massachusetts Institute of Technology. He received his Ph.D. in Chemistry and M.S. in Polymer Science from Carnegie Mellon University and his B.S. in Chemistry from the Philadelphia College of Pharmacy and Science.
About BIND Therapeutics
BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its Medicinal Nanoengineering® platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND's lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer.
BIND has announced collaborations with Amgen Inc., Pfizer Inc. and AstraZeneca AB to develop Accurins based on therapeutic payloads from their product pipelines. BIND's platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women's Hospital/Harvard Medical School of BIND's scientific founders and directors Dr. Robert Langer and Dr. Omid Farokhzad. For more information, please visit the company's web site at www.bindtherapeutics.com.